United States Patent 7,750,029: Mirabegron Overactive-Bladder Method Claims and Patent Landscape

U.S. Patent No. 7,750,029 covers the use of mirabegron, including its salts and free-base form, to treat overactive bladder in non-diabetic patients. The patent is narrower than a composition-of-matter patent because it requires a therapeutic method, a specific active ingredient, overactive bladder, and a patient who is not suffering from diabetes. The patent issued to Astellas Pharma Inc. on July 6, 2010, from an application filed December 28, 2005, and has a statutory patent-term date based on the 2005 filing date of December 28, 2025, subject to any patent-term adjustment.[1]

The claims can read on treatment with Myrbetri, whose active ingredient is mirabegron. The patent does not broadly cover all beta-3 adrenergic agonists, all urinary disorders, or all uses of mirabegron.

What drug and therapeutic use does U.S. Patent 7,750,029 cover?

The claimed compound is mirabegron, chemically identified as:

(R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide.

Mirabegron is a selective beta-3 adrenergic receptor agonist. The FDA approved mirabegron extended-release tablets under the brand name Myrbetri for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.[2]

The patent claims treatment of overactive bladder by administering a pharmaceutically effective amount of mirabegron. The therapeutic use is directed to a particular patient population: subjects who are not suffering from diabetes.

What are the principal claim limitations?

Claim element	Requirement
Disease	Overactive bladder
Active ingredient	Mirabegron
Dosage concept	A pharmaceutically effective amount
Patient limitation	Subject is not suffering from diabetes
Claim 1 chemical form	Mirabegron or a salt
Claim 6 chemical form	Mirabegron in free-base form
Optional patient type	Human
Optional underlying cause	Benign prostatic hyperplasia
Optional symptoms	Urinary urgency, urge incontinence, or pollakiuria

The patent therefore has both composition-form distinctions and disease-subpopulation limitations. Claim 1 covers mirabegron and its salts. Claim 6 separately covers the free base. Claims 11 and 12 narrow the claims to human treatment.

How should the independent claims be interpreted?

What does claim 1 protect?

Claim 1 requires all of the following:

A method for treating overactive bladder.
Administration to a subject in need of treatment.
A pharmaceutically effective amount of mirabegron or a salt.
A subject who is not suffering from diabetes.

A product is not infringing claim 1 merely because it contains mirabegron. The claim requires use of the product in a method for treating overactive bladder and requires the non-diabetic patient limitation.

The phrase "not suffering from diabetes" is a negative limitation. It excludes treatment of diabetic patients from the literal scope of the claim. It does not require that the patient be healthy in every other respect. A patient with hypertension, benign prostatic hyperplasia, renal impairment, or other conditions could fall within the claim if the patient is not suffering from diabetes and the remaining limitations are satisfied.

What does claim 6 add?

Claim 6 is similar to claim 1 but expressly requires mirabegron in its free-base form. It does not cover a salt formulation on its face.

This distinction matters because commercial mirabegron products may use the active pharmaceutical ingredient in a particular solid-state, salt, hydrate, or formulation form. A formulation containing free-base mirabegron may implicate claim 6, while a salt formulation may fall primarily within claim 1, assuming the treatment and patient limitations are met.

The claim language does not expressly require:

A particular dose.
A specific dosing frequency.
An extended-release tablet.
A particular route of administration.
A particular treatment duration.
A particular severity of overactive bladder.
A particular age range.
A particular geographic market.

Those limitations could arise from other patents, the product label, prosecution history, or infringement evidence, but they are not stated in claims 1 or 6.

What do the dependent claims cover?

Claims 2 through 5 depend from claim 1. Claims 7 through 10 depend from claim 6. They narrow the use as follows:

Claims	Additional limitation
2 and 7	Overactive bladder resulting from benign prostatic hyperplasia
3 and 8	Urinary urgency
4 and 9	Urinary urge incontinence
5 and 10	Pollakiuria, or urinary frequency
11	Human subject under claim 1
12	Human subject under claim 6

The BPH claims are clinically important because male patients with benign prostatic hyperplasia can experience both obstructive and storage-related urinary symptoms. The claim does not cover every patient with BPH. It requires that the overactive bladder be a result of BPH.

The symptom claims may be easier to apply to the approved product label because urgency, urge urinary incontinence, and increased urinary frequency are core overactive-bladder symptoms identified in regulatory materials.[2]

How broad is the patent’s legal scope?

The patent is a method-of-treatment patent with moderate claim breadth and several material restrictions.

What the patent does cover

The claims can cover:

Administration of mirabegron to a non-diabetic human with overactive bladder.
Treatment of overactive bladder associated with BPH.
Treatment of urgency.
Treatment of urge urinary incontinence.
Treatment of urinary frequency.
Use of mirabegron in free-base form.
Use of a pharmaceutically acceptable mirabegron salt.

What the patent does not expressly cover

The claims do not expressly cover:

Mirabegron as a chemical compound without a treatment step.
Manufacturing mirabegron.
A tablet, capsule, suspension, or other dosage form as a product.
Treatment of diabetes.
Treatment of hypertension or cardiovascular disease generally.
Treatment of interstitial cystitis, stress incontinence, or unrelated urinary disorders.
All beta-3 agonists.
A method lacking an overactive-bladder indication.
A patient who is not suffering from diabetes but is treated for a different condition.

The "subject in need thereof" language also requires a therapeutic context. Routine administration to a subject without overactive bladder would present a substantial noninfringement argument.

What is the patent’s prosecution and term profile?

Event	Date or status
Earliest claimed priority	December 28, 2004, based on the Japanese priority record
U.S. application filing	December 28, 2005
U.S. patent issuance	July 6, 2010
Patent number	U.S. 7,750,029
Applicant/assignee	Astellas Pharma Inc.
Statutory term baseline	20 years from the relevant U.S. filing date
Baseline expiration date	December 28, 2025, before any patent-term adjustment
Patent type	Method of treatment
Active ingredient	Mirabegron

The international family was directed to remedies for overactive bladder and related mirabegron uses. The family should be distinguished from earlier compound patents and later formulation, dosage, crystalline-form, and combination patents.

The exact enforceable expiration date must be calculated from the USPTO patent-term-adjustment record and any terminal disclaimer. The 2025 date is the statutory baseline, not a substitute for the USPTO term calculation.[1]

What is the Orange Book status of U.S. Patent 7,750,029?

The Orange Book is the FDA’s principal listing for patents submitted by approved drug applicants in connection with approved products.[3] A method-of-use patent can be listed when it covers an approved use and meets FDA listing requirements.

The commercial relevance of U.S. Patent 7,750,029 depends on three separate questions:

Whether Astellas listed the patent for Myrbetri.
Whether the listed use corresponds to the approved overactive-bladder indication.
Whether the patent remained unexpired and enforceable at the time of an ANDA certification.

A listed method-of-use patent can generate a Paragraph IV certification and a 30-month stay if the brand sponsor files an infringement action within the statutory period. A generic applicant may also submit a section viii statement carving out the patented method, if the remaining label does not encourage use covered by the patent.[4]

Because the claims track the approved overactive-bladder indication, the patent presents a greater Orange Book and label-carve-out issue than a patent directed to an unrelated disease or an unapproved population.

When does U.S. Patent 7,750,029 lose exclusivity?

The statutory baseline expiration date is December 28, 2025. The practical loss of exclusivity can occur earlier or later depending on:

Patent-term adjustment.
Any terminal disclaimer.
Pediatric exclusivity.
The timing of ANDA approval.
Whether the patent is listed in the Orange Book.
Whether a generic label includes the patented use.
Whether the patent survives validity or infringement challenges.

Patent expiration removes the ability to enforce the patent against conduct occurring after expiration. It does not automatically invalidate other mirabegron patents. A generic launch may remain blocked by separate patents covering the compound, formulation, dosage regimen, polymorph, manufacturing process, or other approved uses.

FDA regulatory exclusivity is separate from patent exclusivity. Myrbetri was approved on June 28, 2012.[2] The product’s five-year new chemical entity exclusivity would have expired in 2017. Any later market protection would depend on other regulatory exclusivities and patent rights, not the original NCE period.

What other patents protect mirabegron and Myrbetri?

U.S. Patent 7,750,029 should be analyzed as one layer of a broader estate.

Composition-of-matter patents

Earlier patents in the mirabegron family may provide stronger protection than the asserted method claims because composition claims can reach the drug itself, regardless of the indication. A composition patent generally creates a higher generic-entry barrier than a method patent that depends on a specific patient population.

Formulation and dosage-form patents

Myrbetri is an extended-release oral product. Separate patents may cover:

Extended-release tablets.
Release-controlling excipients.
Dissolution profiles.
Specific dose strengths.
Stable solid forms.
Tablet manufacturing parameters.

These patents can remain relevant after expiration of a method patent. A generic applicant can sometimes avoid a formulation patent by using a noninfringing release technology, but bioequivalence and regulatory requirements constrain design options.

Method-of-use patents

U.S. Patent 7,750,029 is a method-of-use patent focused on non-diabetic overactive-bladder patients. Later use patents may cover dosing, patient subgroups, combination therapy, or other urological conditions.

Manufacturing and process patents

Process patents can protect synthesis routes, intermediates, crystallization, impurity control, or scale-up methods. They usually create a weaker launch barrier than a composition patent because a generic manufacturer can adopt a noninfringing route. They can still increase technical and supply-chain risk.

Which companies are challenging mirabegron exclusivity?

Generic entry depends on ANDA applicants filing Paragraph IV certifications against listed patents. Publicly relevant challengers may include generic manufacturers that submit ANDAs for mirabegron extended-release tablets, but the presence of an ANDA does not establish infringement, invalidity, or FDA approval.

For U.S. Patent 7,750,029, the material legal questions are:

Whether an ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.
Whether the applicant omits or carves out the patented overactive-bladder use.
Whether Astellas files an infringement action.
Whether the FDA imposes a 30-month stay.
Whether a settlement permits an authorized or licensed generic launch.

A Paragraph IV challenge to a separate formulation or composition patent does not necessarily challenge U.S. Patent 7,750,029. Each patent requires a separate certification and infringement analysis.

What patent litigation and settlement issues affect the patent?

A litigation review should separate four issues:

Issue	Relevance to U.S. 7,750,029
Claim construction	Meaning of "treating," "overactive bladder," "pharmaceutically effective amount," and "not suffering from diabetes"
Infringement	Whether the proposed label and actual use meet every claim limitation
Validity	Anticipation, obviousness, written description, enablement, and indefiniteness
Regulatory procedure	Paragraph IV certification, section viii carve-out, and 30-month stay

The strongest noninfringement argument is usually based on the patient or use limitation. A generic label that omits the patented indication may avoid literal inducement, but FDA labeling and promotional materials are assessed together. A label that identifies the same overactive-bladder symptoms, especially urgency, urge incontinence, and urinary frequency, can create greater inducement risk.

A patent settlement could establish a licensed launch date before the patent’s expiration, an authorized generic arrangement, or restrictions on label content. Settlement terms are often confidential, and an agreement involving another Myrbetri patent does not establish the status of this patent.

How strong is the patent estate?

U.S. Patent 7,750,029 has moderate standalone strength and higher value as part of a layered estate.

Strengths

It covers the principal commercial indication for mirabegron.
The claims identify the active ingredient precisely.
Claims cover both salt and free-base forms through separate independent claims.
Dependent claims align with core overactive-bladder symptoms.
Human-treatment claims reduce the relevance of purely experimental or veterinary use.

Weaknesses

The patent does not cover mirabegron as a product.
The non-diabetic limitation narrows infringement exposure.
The method claims require proof of the treatment purpose.
The BPH claims require causation between BPH and overactive bladder.
Generic applicants may attempt a section viii carve-out.
The baseline term ends in 2025, subject to adjustment.
Validity may be challenged based on prior clinical or patent disclosures concerning mirabegron and beta-3 agonists.

The patent’s commercial leverage is therefore highest when combined with Orange Book-listed composition and formulation patents.

How does mirabegron compare with competing overactive-bladder drugs?

Drug	Mechanism	Main product	Patent-risk profile
Mirabegron	Beta-3 adrenergic agonist	Myrbetri	Layered composition, formulation, and method estate
Vibegron	Beta-3 adrenergic agonist	Gemtesa	Later product with its own composition and formulation estate
Solifenacin	Muscarinic antagonist	Vesicare	Older composition and formulation estate; generic competition
Oxybutynin	Antimuscarinic	Ditropan and generics	Mature generic market
Fesoterodine	Antimuscarinic	Toviaz	Product and formulation patents, with generic-entry exposure

Mirabegron’s principal differentiation is mechanism. It may avoid some anticholinergic tolerability issues, but the commercial product remains exposed to patent barriers tied to its active ingredient, dosage form, and approved use.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiration

A generic applicant launches after the final enforceable patent expires. This is the lowest litigation-risk scenario but may still be delayed by regulatory review, manufacturing readiness, and commercial supply.

Scenario 2: Section viii label carve-out

The applicant removes the patented use from the label while retaining non-patented uses. This strategy depends on whether the remaining label avoids encouraging infringement.

Scenario 3: Paragraph IV litigation and settlement

The applicant challenges validity or infringement. A settlement may allow entry before the patent’s expiration date, often with an agreed launch date or license.

Scenario 4: At-risk launch

The applicant launches before final resolution. This exposes the company to damages and possible injunctive relief if the patent is found valid and infringed.

Scenario 5: Noninfringing formulation launch

The applicant uses a different release mechanism or solid form while maintaining bioequivalence. This approach may avoid formulation patents but does not by itself avoid method-of-use claims.

What geographic rights does the patent provide?

U.S. Patent 7,750,029 provides rights only in the United States. Related national patents may exist in Europe, Japan, Canada, Australia, and other jurisdictions, but each country applies separate rules on:

Patent validity.
Claim construction.
Patent-term adjustment.
Supplementary protection certificates.
Use claims.
Regulatory linkage.
Generic approval timing.

A U.S. expiration date does not determine foreign expiry dates. Commercial launch planning requires a country-by-country family review.

Key Takeaways

U.S. Patent 7,750,029 covers mirabegron treatment of overactive bladder in patients who are not suffering from diabetes.
Claim 1 covers mirabegron and its salts; claim 6 covers the free base.
Claims 2 through 5 and 7 through 10 target BPH-related overactive bladder and core symptoms.
Claims 11 and 12 limit treatment to humans.
The patent does not cover mirabegron as a chemical product or all mirabegron uses.
The statutory baseline expiration date is December 28, 2025, subject to USPTO patent-term adjustment and other term extensions.
The patent’s commercial value depends heavily on other composition, formulation, dosage, and manufacturing patents.
Generic applicants may pursue Paragraph IV certifications, section viii carve-outs, litigation, settlement, or post-expiration entry.
The strongest infringement issues concern the indication, patient population, label wording, and actual use.
Patent status must be reviewed separately from FDA exclusivity and Orange Book listing status.

FAQs

Does U.S. Patent 7,750,029 cover Myrbetri tablets themselves?

No. It covers a method of treating overactive bladder using mirabegron or a salt. It is not a product claim directed to a tablet or other dosage form.

Can a generic mirabegron product avoid this patent by using a different formulation?

A different formulation may avoid separate formulation claims, but it does not automatically avoid the method claims. The generic label and intended use must also be assessed against the overactive-bladder and non-diabetic-patient limitations.

Does treatment of a diabetic patient infringe the claims?

The claims expressly require a subject who is not suffering from diabetes. Treatment of a diabetic patient would not satisfy that limitation literally, although separate patents or other legal theories could remain relevant.

Does a label for urinary frequency implicate the patent?

It may. Urinary frequency, identified as pollakiuria in the claims, is expressly covered by claims 5 and 10 when the other limitations are satisfied.

Is the patent still relevant after its December 2025 baseline expiration date?

It may remain relevant if patent-term adjustment, pediatric exclusivity, or another enforceable term extension applies. Separate mirabegron patents may also continue to restrict generic entry after this patent expires.

References

United States Patent and Trademark Office. (2010). U.S. Patent No. 7,750,029, Remedies for overactive bladder.
U.S. Food and Drug Administration. (2012). Myrbetri (mirabegron) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2017). Abbreviated new drug application regulations and patent certifications, 21 C.F.R. § 314.107.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2002-323792	Nov 07, 2002

PCT Information
PCT Filed	November 04, 2003	PCT Application Number:	PCT/JP03/14065
PCT Publication Date:	May 21, 2004	PCT Publication Number:	WO2004/041276

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1559427	⤷ Start Trial	C300599	Netherlands	⤷ Start Trial
European Patent Office	1559427	⤷ Start Trial	CA 2013 00028	Denmark	⤷ Start Trial
European Patent Office	1559427	⤷ Start Trial	92218	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,750,029